JP2004275169A - ｓｉＲＮＡを用いたヒトミッドカインの発現の強い抑制。 - Google Patents
ｓｉＲＮＡを用いたヒトミッドカインの発現の強い抑制。 Download PDFInfo
- Publication number
- JP2004275169A JP2004275169A JP2003117617A JP2003117617A JP2004275169A JP 2004275169 A JP2004275169 A JP 2004275169A JP 2003117617 A JP2003117617 A JP 2003117617A JP 2003117617 A JP2003117617 A JP 2003117617A JP 2004275169 A JP2004275169 A JP 2004275169A
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- human
- expression
- cells
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 51
- 101000990990 Homo sapiens Midkine Proteins 0.000 title claims abstract description 14
- 230000014509 gene expression Effects 0.000 title claims abstract description 13
- 102000053521 human MDK Human genes 0.000 title claims abstract description 13
- 230000005764 inhibitory process Effects 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 108010092801 Midkine Proteins 0.000 description 51
- 102000016776 Midkine Human genes 0.000 description 50
- 239000004055 small Interfering RNA Substances 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 101001046529 Homo sapiens Mevalonate kinase Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001046530 Mus musculus Mevalonate kinase Proteins 0.000 description 1
- 101000990991 Mus musculus Midkine Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003117617A JP2004275169A (ja) | 2003-03-17 | 2003-03-17 | ｓｉＲＮＡを用いたヒトミッドカインの発現の強い抑制。 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003117617A JP2004275169A (ja) | 2003-03-17 | 2003-03-17 | ｓｉＲＮＡを用いたヒトミッドカインの発現の強い抑制。 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004275169A true JP2004275169A (ja) | 2004-10-07 |
| JP2004275169A5 JP2004275169A5 (enExample) | 2005-08-11 |
Family
ID=33296313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003117617A Pending JP2004275169A (ja) | 2003-03-17 | 2003-03-17 | ｓｉＲＮＡを用いたヒトミッドカインの発現の強い抑制。 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004275169A (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006126600A1 (ja) * | 2005-05-25 | 2006-11-30 | National University Corporation Nagoya Universtiy | 血管閉塞性疾患用医薬組成物 |
| CN1314698C (zh) * | 2004-11-05 | 2007-05-09 | 浙江大学 | 针对中期因子基因的小干扰核糖核酸分子及其用途 |
| WO2007055378A1 (ja) | 2005-11-14 | 2007-05-18 | Cell Signals Inc. | 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法 |
-
2003
- 2003-03-17 JP JP2003117617A patent/JP2004275169A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314698C (zh) * | 2004-11-05 | 2007-05-09 | 浙江大学 | 针对中期因子基因的小干扰核糖核酸分子及其用途 |
| WO2006126600A1 (ja) * | 2005-05-25 | 2006-11-30 | National University Corporation Nagoya Universtiy | 血管閉塞性疾患用医薬組成物 |
| JPWO2006126600A1 (ja) * | 2005-05-25 | 2008-12-25 | 国立大学法人名古屋大学 | 血管閉塞性疾患用医薬組成物 |
| WO2007055378A1 (ja) | 2005-11-14 | 2007-05-18 | Cell Signals Inc. | 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE46873E1 (en) | Multi-targeted RNAi therapeutics for scarless wound healing of skin | |
| Guan et al. | A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model | |
| WO2009151539A1 (en) | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS | |
| US9453050B2 (en) | Compositions for treating glioma | |
| JP6895175B2 (ja) | エクソソーム分泌阻害剤 | |
| Cho et al. | The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP | |
| Zhao et al. | Circular RNA WRNIP1 activates the PI3K-AKT and ERK1/2 signaling pathways by binding to miR-129-5p/IGF2 axis and facilitates ovarian follicle development in chickens | |
| JP2010536365A5 (enExample) | ||
| Meng et al. | Loss of histone methyltransferase kmt2d attenuates angiogenesis in the ischemic heart by inhibiting the transcriptional activation of vegf-A | |
| Ishida et al. | CRISPR–Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis | |
| JP2004275169A (ja) | ｓｉＲＮＡを用いたヒトミッドカインの発現の強い抑制。 | |
| JP2007523658A (ja) | アレルギー性疾患を治療するための物質および方法 | |
| KR20150069375A (ko) | 줄기세포로부터 연골세포로의 분화 촉진용 조성물 | |
| EP2243828A1 (en) | Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy | |
| KR101496610B1 (ko) | 줄기세포의 근육 세포로의 분화 유도용 조성물 | |
| Huang et al. | Regulatory mechanism of lncRNA CTBP1-AS2 in nasopharyngeal carcinoma cell proliferation and apoptosis via the miR-140-5p/BMP2 Axis | |
| Cho et al. | Suppression of PAI‐1 expression through inhibition of the EGFR‐mediated signaling cascade in rat kidney fibroblast by ascofuranone | |
| US7960363B2 (en) | Therapeutic agent for wounds and screening method for the same | |
| JP2008511302A (ja) | Ｐ２ｘ７レセプター発現を阻害する方法及び組成物 | |
| KR101229821B1 (ko) | 그래뉼린-에피테린 전구체 유전자의 발현을 억제하는 안티센스 및 이를 함유하는 약제학적 조성물 | |
| Udagawa et al. | c-fos antisense DNA inhibits proliferation of osteoclast progenitors in osteoclast development but not macrophage differentiation in vitro | |
| JP4480125B2 (ja) | ｓｉＲＮＡを用いたヒト血管内皮増殖因子の発現の強い抑制。 | |
| CN100374573C (zh) | 一种可稳定表达VEGF shRNA的载体pCD-VEGF | |
| US20190085330A1 (en) | miRNAs USEFUL FOR IDENTIFYING TARGETS ASSOCIATED WITH CANCER | |
| CN116769828B (zh) | 调控nrf2转录因子活性的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050107 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050107 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050117 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050117 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050107 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060405 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071113 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080328 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080819 |